<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03687684</url>
  </required_header>
  <id_info>
    <org_study_id>TAK-831-1002</org_study_id>
    <secondary_id>U1111-1219-2623</secondary_id>
    <secondary_id>JapicCTI-184127</secondary_id>
    <nct_id>NCT03687684</nct_id>
  </id_info>
  <brief_title>Phase 1 Study of TAK-831 in Healthy Adult Asian Subjects</brief_title>
  <official_title>Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of TAK 831 in Healthy Adult Asian Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate safety, tolerability, pharmacokinetics, and
      pharmacodynamics of TAK-831 when administered as single or multiple oral doses in healthy
      adult Asian participants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The drug being tested in this study is called TAK-831. This study will assess the safety,
      tolerability, pharmacokinetics (PK), and Pharmacodynamics (PD) of TAK-831 when administered
      as single or multiple oral doses in healthy adult Asian participants (Japanese and Chinese
      participants).

      The study will enroll approximately 40 participants and include up to 5 cohorts of healthy
      adult Japanese or Chinese participants as following (8 participants per a cohort). Cohorts 3,
      4 and 5 are optional and will be decided to run based on the data of Cohorts 1 and 2. Dose
      level for these cohorts will be defined based on the result of Cohort 1 or Cohort 2.

        -  Japanese Cohort 1-A; TAK-831 100 mg single dose + TAK-831 300 mg single dose

        -  Japanese Cohort 1-B; TAK-831 100 mg single dose + Placebo single dose

        -  Japanese Cohort 1-C; Placebo single dose + TAK-831 300 mg single dose

        -  Japanese Cohort 2; TAK-831 300 mg or TAK-831 matching placebo, single dose + TAK-831 300
           mg or TAK-831 matching placebo, multiple dose *

        -  Chinese Cohort 3; TAK-831 600 mg or TAK-831 matching placebo, single dose + TAK-831 600
           mg or TAK-831 matching placebo, multiple dose

        -  Japanese Cohort 4; TAK-831 600 mg or TAK-831 matching placebo, single dose + TAK-831 600
           mg or TAK-831 matching placebo, multiple dose

        -  Japanese Cohort 5; TAK-831 50 mg or TAK-831 matching placebo, single dose + TAK-831 50
           mg or TAK-831 matching placebo, multiple dose *The dose in Cohort 2 will be adjusted
           based on the safety and tolerability as well as PK and PD in Cohort 1.

      Above all treatment, randomization information will remain undisclosed to the participant and
      study doctor during the study (unless there is an urgent medical need) and TAK-831 will be
      administered orally.

      This single center trial will be conducted in Japan. The overall time to participate in
      Cohort 1 of this study is approximately 12 days and 19 days in Cohorts 2 to 5. 11 days (for
      Cohort 1) or 12 days (for Cohorts 2 to 5) after last dose of study drug, participants will be
      contacted by telephone for a follow-up assessment unless abnormal, clinically significant
      findings are observed upon discharge.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 9, 2018</start_date>
  <completion_date type="Actual">June 19, 2019</completion_date>
  <primary_completion_date type="Actual">June 9, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Reporting at Least One Treatment-emergent Adverse Event (TEAE)</measure>
    <time_frame>Cohort 1: Baseline up to Day 23; Cohorts 2-5: Baseline up to Day 31</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Reporting at Least One TEAE Related to Laboratory Test Results</measure>
    <time_frame>Cohort 1: Baseline up to Day 23; Cohorts 2-5: Baseline up to Day 31</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Reporting at Least One TEAE Related to Vital Sign</measure>
    <time_frame>Cohort 1: Baseline up to Day 23; Cohorts 2-5: Baseline up to Day 31</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Reporting at Least One TEAE Related to Body Weight</measure>
    <time_frame>Cohort 1: Baseline up to Day 23; Cohorts 2-5: Baseline up to Day 31</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Reporting at Least One TEAE Related to 12-lead Electrocardiogram (ECG) Parameters</measure>
    <time_frame>Cohort 1: Baseline up to Day 23; Cohorts 2-5: Baseline up to Day 31</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax: Maximum Observed Plasma Concentration for TAK-831</measure>
    <time_frame>Cohort 1: Day 1 pre-dose and at 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48 and 72 hours post-dose; Cohorts 2 to 5: Day 1 pre-dose and at 0.25, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48 and 72 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohorts 2 to 5, Cmax, ss: Maximum Observed Steady-state Plasma Concentration During a Dosing Interval for TAK-831</measure>
    <time_frame>Day 17 pre-dose and at 0.25, 0.5, 1, 1.5, 2, 4, 8, 12 and 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-831</measure>
    <time_frame>Cohort 1: Day 1 pre-dose, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48, 72 hours post-dose; Cohorts 2 to 5: Day 1 pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48, 72 hours post-dose; Day 17 pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 8, 12, 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUClast: Area Under the Plasma Concentration-time Curve (AUC) From Time 0 to Time of the Last Quantifiable Concentration for TAK-831</measure>
    <time_frame>Cohort 1: Day 1 pre-dose and at 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48 and 72 hours post-dose; Cohorts 2 to 5: Day 1 pre-dose and at 0.25, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48 and 72 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCâˆž: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-831</measure>
    <time_frame>Cohort 1: Day 1 pre-dose and at 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48 and 72 hours post-dose; Cohorts 2 to 5: Day 1 pre-dose and at 0.25, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48 and 72 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohorts 2 to 5, AUCtau: Area Under the Plasma Concentration-time Curve From Time 0 to [Time] Over the Dosing Interval for TAK-831</measure>
    <time_frame>Day 1: pre-dose and at 0.25, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48 and 72 hours post-dose and Day 17: pre-dose and at 0.25, 0.5, 1, 1.5, 2, 4, 8, 12, and 24 hours post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Japanese Cohort 1-A; TAK-831 100 mg + TAK-831 300 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-831 100 milligrams (mg), tablets, orally, once daily on Day 1, followed by TAK-831 300 mg, tablets, orally, once daily on Day 9 in healthy Japanese participants.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Japanese Cohort 1-B; TAK-831 100 mg + Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-831 100 mg, tablets, orally, once daily on Day 1 followed by TAK-831 matching placebo, tablets, orally, once daily on Day 9 in healthy Japanese participants.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Japanese Cohort 1-C; Placebo + TAK-831 300 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-831 matching placebo, tablets, orally, once daily on Day 1 followed by TAK-831 300 mg, tablets, orally, once daily on Day 9 in healthy Japanese participants.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Japanese Cohort 2; TAK-831 300 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-831 300 mg or TAK-831 matching placebo, tablets, orally, once daily on Day 1 followed by TAK-831 300 mg or TAK-831 matching placebo, tablets, orally, once daily from Day 4 to Day 17 in healthy Japanese participants.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chinese Cohort 3; TAK-831 600 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-831 600 mg or TAK-831 matching placebo, tablets, orally, once daily on Day 1 followed by TAK-831 600 mg or TAK-831 matching placebo, tablets, orally, once daily from Day 4 to Day 17 in healthy Chinese participants. This cohort is optional and will be decided to run based on the data of Cohorts 1 and 2. The dose will be defined based on the result of Cohort 1 or Cohort 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Japanese Cohort 4; TAK-831 600 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-831 600 mg or TAK-831 matching placebo, tablets, orally, once daily on Day 1 followed by TAK-831 600 mg or TAK-831 matching placebo, tablets, orally, once daily from Day 4 to Day 17 in healthy Japanese participants. This cohort is optional and will be decided to run based on the data of Cohorts 1 and 2. The dose will be defined based on the result of Cohort 1 or Cohort 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Japanese Cohort 5; TAK-831</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-831 50 mg or TAK-831 matching placebo, tablets, orally, once daily on Day 1 followed by TAK-831 50 mg or TAK-831 matching placebo, tablets, orally, once daily from Day 4 to Day 17 in healthy Japanese participants.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-831</intervention_name>
    <description>TAK-831 Tablets.</description>
    <arm_group_label>Chinese Cohort 3; TAK-831 600 mg</arm_group_label>
    <arm_group_label>Japanese Cohort 1-A; TAK-831 100 mg + TAK-831 300 mg</arm_group_label>
    <arm_group_label>Japanese Cohort 1-B; TAK-831 100 mg + Placebo</arm_group_label>
    <arm_group_label>Japanese Cohort 1-C; Placebo + TAK-831 300 mg</arm_group_label>
    <arm_group_label>Japanese Cohort 2; TAK-831 300 mg</arm_group_label>
    <arm_group_label>Japanese Cohort 4; TAK-831 600 mg</arm_group_label>
    <arm_group_label>Japanese Cohort 5; TAK-831</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>TAK-831 Matching Placebo Tablets.</description>
    <arm_group_label>Chinese Cohort 3; TAK-831 600 mg</arm_group_label>
    <arm_group_label>Japanese Cohort 1-B; TAK-831 100 mg + Placebo</arm_group_label>
    <arm_group_label>Japanese Cohort 1-C; Placebo + TAK-831 300 mg</arm_group_label>
    <arm_group_label>Japanese Cohort 2; TAK-831 300 mg</arm_group_label>
    <arm_group_label>Japanese Cohort 4; TAK-831 600 mg</arm_group_label>
    <arm_group_label>Japanese Cohort 5; TAK-831</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The participant must understand the study procedures and agree to participate by
             providing written informed consent (for Chinese participants, an interpreter should be
             present as necessary).

          2. The participant must be willing and able to comply with all study procedures and
             restrictions.

          3. The participant must be male or female (of nonchildbearing potential) aged 20 to 55
             years, inclusive, at the Screening.

          4. The participant must have a body mass index (BMI) &gt;=18.5 kg/m^2 and =&lt;25.0 kg/m^2 at
             the Screening.

          5. The participant must be a current nonsmoker who has not used tobacco- or
             nicotine-containing products (e.g., nicotine patch) for at least 6 months prior to the
             Screening.

          6. Chinese participants are defined as participants who were born in mainland China, and
             their biological parents and grandparents must all have been of Chinese origin (for
             Cohort 3 only).

          7. Chinese participants who have lived out of China for more than 5 years must not have
             significantly modified their diets since leaving China (for Cohort 3 only).

          8. The participant must be judged to be in good health by the investigator, based on
             clinical evaluations including laboratory tests, medical history, full physical
             examination, 12-lead electrocardiogram, and vital sign measurements performed at the
             Screening and prior to the first dose of study drug.

          9. The participant must meet the birth control requirements.

        Exclusion Criteria:

          1. The participant has a history of clinically significant endocrine, gastrointestinal
             (including motility disorder and intestinal obstruction), cardiovascular,
             hematological, hepatic, immunological, renal, respiratory, or genitourinary, or
             presents with major neurological (including stroke and chronic seizures) abnormalities
             or diseases.

          2. The participant has participated in another investigational trial within 4 weeks
             before the pretrial visit (Screening). The 4-week window will be derived from the date
             of the last trial procedure and/or adverse event (AE) related to the trial procedure
             in the previous trial to the Screening Visit of the current trial.

          3. The participant is an employee or immediate family member (e.g., spouse, parent,
             child, sibling) of the sponsor.

          4. The participant has a history of cancer (malignancy).

          5. The participant has a history of significant multiple and/or severe allergies (e.g.,
             food, drug, latex allergy) or has had an anaphylactic reaction or significant
             intolerability to prescription or nonprescription drugs or food.

          6. The participant has a positive alcohol or drug or immunological screen.

          7. The participant is of childbearing potential or lactating.

          8. The participant had major surgery, received or lost 1 unit of blood (approximately 500
             milliliters [mL]) within 8 weeks prior to the first dose of study drug.

          9. The participant with any gastrointestinal (GI) surgery that could impact upon the
             absorption of study drug.

         10. The participant has a known hypersensitivity to any component of the formulation of
             TAK-831 or related compounds.

         11. The participant is unable to refrain from or anticipates the use of any medication,
             including prescription and nonprescription drugs or herbal remedies, beginning
             approximately 7 days before administration of the initial dose of trial drug,
             throughout the trial (including washout intervals between trial periods), until the
             Follow-up Visit.

         12. The participant has a history of alcohol consumption exceeding 2 standard drinks per
             day on average (1 glass is approximately equivalent to: beer [354 mL/12 ounces], wine
             [118 mL/4 ounces], or distilled spirits [29.5 mL/1 ounce] per day).

         13. The participant who consumes excessive amounts, defined as greater than 6 servings (1
             serving is approximately equivalent to 120 mg of caffeine) of coffee, tea, cola,
             energy drinks, or other caffeinated beverages per day.

         14. The participant has a history of drug abuse.

         15. The participant has a (QT interval with Fridericia's correction method) QTcF &gt;450
             milliseconds (msec) (males) or &gt;470 msec (females) or PR outside the range of 120 to
             220 msec at the Screening Visit or Check-in.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Research Hospital Tokyo</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>September 26, 2018</study_first_submitted>
  <study_first_submitted_qc>September 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2018</study_first_posted>
  <results_first_submitted>June 5, 2020</results_first_submitted>
  <results_first_submitted_qc>June 5, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 29, 2020</results_first_posted>
  <last_update_submitted>June 5, 2020</last_update_submitted>
  <last_update_submitted_qc>June 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Takeda makes patient-level, de-identified data sets and associated documents available for all interventional studies after applicable marketing approvals and commercial availability have been received (or program is completely terminated), an opportunity for the primary publication of the research and final report development has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 26, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/84/NCT03687684/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 27, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/84/NCT03687684/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at single site in Japan from 09 October 2018 to 19 June 2019.</recruitment_details>
      <pre_assignment_details>Healthy adult participants were randomized to receive TAK-831: under 3-sequential dose escalation design to the sequence of administration of A (100 mg +300 mg), B (100 mg + Placebo), and C (Placebo + 300 mg) in Cohort 1 (Japanese); single dose followed by multiple dose of TAK-831 or Placebo in Cohorts 2, 4, 5 (Japanese) and in Cohort 3 (Chinese).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Japanese Cohort 1-A: TAK-831 100 mg + TAK-831 300 mg</title>
          <description>TAK-831 100 milligram (mg), tablet, orally, once on Day 1 of Part 1, followed by TAK-831 300 mg, tablet, orally, once on Day 1 (Day 9) of Part 2 in healthy Japanese participants.</description>
        </group>
        <group group_id="P2">
          <title>Japanese Cohort 1-B: TAK-831 100 mg + Placebo</title>
          <description>TAK-831 100 mg, tablet, orally, once on Day 1 of Part 1 followed by TAK-831 matching placebo, tablet, orally, once on Day 1 (Day 9) of Part 2 in healthy Japanese participants.</description>
        </group>
        <group group_id="P3">
          <title>Japanese Cohort 1-C: Placebo + TAK-831 300 mg</title>
          <description>TAK-831 matching placebo, tablet, orally, once on Day 1 of Part 1 followed by TAK-831 300 mg, tablet, orally, once on Day 1 (Day 9) of Part 2 in healthy Japanese participants.</description>
        </group>
        <group group_id="P4">
          <title>Japanese Cohort 2, 4 and 5: Pooled Placebo</title>
          <description>TAK-831 matching placebo, tablet, orally, once on Day 1 and once daily from Day 4 to Day 17 in healthy Japanese participants.</description>
        </group>
        <group group_id="P5">
          <title>Japanese Cohort 2: TAK-831 300 mg</title>
          <description>TAK-831 300 mg, tablet, orally, once on Day 1 and once daily from Day 4 to Day 17 in healthy Japanese participants.</description>
        </group>
        <group group_id="P6">
          <title>Japanese Cohort 4: TAK-831 600 mg</title>
          <description>TAK-831 600 mg, tablet, orally, once on Day 1 and once daily from Day 4 to Day 17 in healthy Japanese participants.</description>
        </group>
        <group group_id="P7">
          <title>Japanese Cohort 5: TAK-831 50 mg</title>
          <description>TAK-831 50 mg, tablet, orally, once on Day 1 and once daily from Day 4 to Day 17 in healthy Japanese participants.</description>
        </group>
        <group group_id="P8">
          <title>Chinese Cohort 3: Placebo</title>
          <description>TAK-831 matching placebo, tablet, orally, once on Day 1 and once daily from Day 4 to Day 17 in healthy Chinese participants.</description>
        </group>
        <group group_id="P9">
          <title>Chinese Cohort 3: TAK-831 600 mg</title>
          <description>TAK-831 600 mg, tablet, orally, once on Day 1 and once daily from Day 4 to Day 17 in healthy Chinese participants.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The safety analysis set was defined as all participants who received at least one dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Japanese Cohort 1-A: TAK-831 100 mg + TAK-831 300 mg</title>
          <description>TAK-831 100 mg, tablet, orally, once on Day 1 of Part 1, followed by TAK-831 300 mg, tablet, orally, once on Day 1 (Day 9) of Part 2 in healthy Japanese participants.</description>
        </group>
        <group group_id="B2">
          <title>Japanese Cohort 1-B: TAK-831 100 mg + Placebo</title>
          <description>TAK-831 100 mg, tablet, orally, once on Day 1 of Part 1 followed by TAK-831 matching placebo, tablet, orally, once on Day 1 (Day 9) of Part 2 in healthy Japanese participants.</description>
        </group>
        <group group_id="B3">
          <title>Japanese Cohort 1-C: Placebo + TAK-831 300 mg</title>
          <description>TAK-831 matching placebo, tablet, orally, once on Day 1 of Part 1 followed by TAK-831 300 mg, tablet, orally, once on Day 1 (Day 9) of Part 2 in healthy Japanese participants.</description>
        </group>
        <group group_id="B4">
          <title>Japanese Cohort 2, 4 and 5: Pooled Placebo</title>
          <description>TAK-831 matching placebo, tablet, orally, once on Day 1 and once daily from Day 4 to Day 17 in healthy Japanese participants.</description>
        </group>
        <group group_id="B5">
          <title>Japanese Cohort 2: TAK-831 300 mg</title>
          <description>TAK-831 300 mg, tablet, orally, once on Day 1 and once daily from Day 4 to Day 17 in healthy Japanese participants.</description>
        </group>
        <group group_id="B6">
          <title>Japanese Cohort 4: TAK-831 600 mg</title>
          <description>TAK-831 600 mg, tablet, orally, once on Day 1 and once daily from Day 4 to Day 17 in healthy Japanese participants.</description>
        </group>
        <group group_id="B7">
          <title>Japanese Cohort 5: TAK-831 50 mg</title>
          <description>TAK-831 50 mg, tablet, orally, once on Day 1 and once daily from Day 4 to Day 17 in healthy Japanese participants.</description>
        </group>
        <group group_id="B8">
          <title>Chinese Cohort 3: Placebo</title>
          <description>TAK-831 matching placebo, tablet, orally, once on Day 1 and once daily from Day 4 to Day 17 in healthy Chinese participants.</description>
        </group>
        <group group_id="B9">
          <title>Chinese Cohort 3: TAK-831 600 mg</title>
          <description>TAK-831 600 mg, tablet, orally, once on Day 1 and once daily from Day 4 to Day 17 in healthy Chinese participants.</description>
        </group>
        <group group_id="B10">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="2"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="6"/>
            <count group_id="B7" value="6"/>
            <count group_id="B8" value="2"/>
            <count group_id="B9" value="6"/>
            <count group_id="B10" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="6"/>
                    <measurement group_id="B10" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="6"/>
                    <measurement group_id="B10" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="6"/>
                    <measurement group_id="B10" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="6"/>
                    <measurement group_id="B10" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reporting at Least One Treatment-emergent Adverse Event (TEAE)</title>
        <time_frame>Cohort 1: Baseline up to Day 23; Cohorts 2-5: Baseline up to Day 31</time_frame>
        <population>The safety analysis set was defined as all participants who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Japanese Cohort 1: Placebo</title>
            <description>TAK-831 matching placebo, tablets, orally, once on Day 1 of Part 1 and Day 1 (Day 9) of Part 2 in healthy Japanese participants.</description>
          </group>
          <group group_id="O2">
            <title>Japanese Cohort 1: TAK-831 100 mg</title>
            <description>TAK-831 100 mg, tablet, orally, once on Day 1 of Part 1 in healthy Japanese participants.</description>
          </group>
          <group group_id="O3">
            <title>Japanese Cohort 1: TAK-831 300 mg</title>
            <description>TAK-831 300 mg, tablet, orally, once on Day 1 (Day 9) of Part 2 in healthy Japanese participants.</description>
          </group>
          <group group_id="O4">
            <title>Japanese Cohort 2, 4 and 5: Pooled Placebo</title>
            <description>TAK-831 matching placebo, tablet, orally, once on Day 1 and once daily from Day 4 to Day 17 in healthy Japanese participants.</description>
          </group>
          <group group_id="O5">
            <title>Japanese Cohort 2: TAK-831 300 mg</title>
            <description>TAK-831 300 mg, tablet, orally, once on Day 1 and once daily from Day 4 to Day 17 in healthy Japanese participants.</description>
          </group>
          <group group_id="O6">
            <title>Japanese Cohort 4: TAK-831 600 mg</title>
            <description>TAK-831 600 mg, tablet, orally, once on Day 1 and once daily from Day 4 to Day 17 in healthy Japanese participants.</description>
          </group>
          <group group_id="O7">
            <title>Japanese Cohort 5: TAK-831 50 mg</title>
            <description>TAK-831 50 mg, tablet, orally, once on Day 1 and once daily from Day 4 to Day 17 in healthy Japanese participants.</description>
          </group>
          <group group_id="O8">
            <title>Chinese Cohort 3: Placebo</title>
            <description>TAK-831 matching placebo, tablet, orally, once on Day 1 and once daily from Day 4 to Day 17 in healthy Chinese participants.</description>
          </group>
          <group group_id="O9">
            <title>Chinese Cohort 3: TAK-831 600 mg</title>
            <description>TAK-831 600 mg, tablet, orally, once on Day 1 and once daily from Day 4 to Day 17 in healthy Chinese participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting at Least One Treatment-emergent Adverse Event (TEAE)</title>
          <population>The safety analysis set was defined as all participants who received at least one dose of study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="2"/>
                <count group_id="O9" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reporting at Least One TEAE Related to Laboratory Test Results</title>
        <time_frame>Cohort 1: Baseline up to Day 23; Cohorts 2-5: Baseline up to Day 31</time_frame>
        <population>The safety analysis set was defined as all participants who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Japanese Cohort 1: Placebo</title>
            <description>TAK-831 matching placebo, tablets, orally, once on Day 1 of Part 1 and Day 1 (Day 9) of Part 2 in healthy Japanese participants.</description>
          </group>
          <group group_id="O2">
            <title>Japanese Cohort 1: TAK-831 100 mg</title>
            <description>TAK-831 100 mg, tablet, orally, once on Day 1 of Part 1 in healthy Japanese participants.</description>
          </group>
          <group group_id="O3">
            <title>Japanese Cohort 1: TAK-831 300 mg</title>
            <description>TAK-831 300 mg, tablet, orally, once on Day 1 (Day 9) of Part 2 in healthy Japanese participants.</description>
          </group>
          <group group_id="O4">
            <title>Japanese Cohort 2, 4 and 5: Pooled Placebo</title>
            <description>TAK-831 matching placebo, tablet, orally, once on Day 1 and once daily from Day 4 to Day 17 in healthy Japanese participants.</description>
          </group>
          <group group_id="O5">
            <title>Japanese Cohort 2: TAK-831 300 mg</title>
            <description>TAK-831 300 mg, tablet, orally, once on Day 1 and once daily from Day 4 to Day 17 in healthy Japanese participants.</description>
          </group>
          <group group_id="O6">
            <title>Japanese Cohort 4: TAK-831 600 mg</title>
            <description>TAK-831 600 mg, tablet, orally, once on Day 1 and once daily from Day 4 to Day 17 in healthy Japanese participants.</description>
          </group>
          <group group_id="O7">
            <title>Japanese Cohort 5: TAK-831 50 mg</title>
            <description>TAK-831 50 mg, tablet, orally, once on Day 1 and once daily from Day 4 to Day 17 in healthy Japanese participants.</description>
          </group>
          <group group_id="O8">
            <title>Chinese Cohort 3: Placebo</title>
            <description>TAK-831 matching placebo, tablet, orally, once on Day 1 and once daily from Day 4 to Day 17 in healthy Chinese participants.</description>
          </group>
          <group group_id="O9">
            <title>Chinese Cohort 3: TAK-831 600 mg</title>
            <description>TAK-831 600 mg, tablet, orally, once on Day 1 and once daily from Day 4 to Day 17 in healthy Chinese participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting at Least One TEAE Related to Laboratory Test Results</title>
          <population>The safety analysis set was defined as all participants who received at least one dose of study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reporting at Least One TEAE Related to Vital Sign</title>
        <time_frame>Cohort 1: Baseline up to Day 23; Cohorts 2-5: Baseline up to Day 31</time_frame>
        <population>The safety analysis set was defined as all participants who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Japanese Cohort 1: Placebo</title>
            <description>TAK-831 matching placebo, tablets, orally, once on Day 1 of Part 1 and Day 1 (Day 9) of Part 2 in healthy Japanese participants.</description>
          </group>
          <group group_id="O2">
            <title>Japanese Cohort 1: TAK-831 100 mg</title>
            <description>TAK-831 100 mg, tablet, orally, once on Day 1 of Part 1 in healthy Japanese participants.</description>
          </group>
          <group group_id="O3">
            <title>Japanese Cohort 1: TAK-831 300 mg</title>
            <description>TAK-831 300 mg, tablet, orally, once on Day 1 (Day 9) of Part 2 in healthy Japanese participants.</description>
          </group>
          <group group_id="O4">
            <title>Japanese Cohort 2, 4 and 5: Pooled Placebo</title>
            <description>TAK-831 matching placebo, tablet, orally, once on Day 1 and once daily from Day 4 to Day 17 in healthy Japanese participants.</description>
          </group>
          <group group_id="O5">
            <title>Japanese Cohort 2: TAK-831 300 mg</title>
            <description>TAK-831 300 mg, tablet, orally, once on Day 1 and once daily from Day 4 to Day 17 in healthy Japanese participants.</description>
          </group>
          <group group_id="O6">
            <title>Japanese Cohort 4: TAK-831 600 mg</title>
            <description>TAK-831 600 mg, tablet, orally, once on Day 1 and once daily from Day 4 to Day 17 in healthy Japanese participants.</description>
          </group>
          <group group_id="O7">
            <title>Japanese Cohort 5: TAK-831 50 mg</title>
            <description>TAK-831 50 mg, tablet, orally, once on Day 1 and once daily from Day 4 to Day 17 in healthy Japanese participants.</description>
          </group>
          <group group_id="O8">
            <title>Chinese Cohort 3: Placebo</title>
            <description>TAK-831 matching placebo, tablet, orally, once on Day 1 and once daily from Day 4 to Day 17 in healthy Chinese participants.</description>
          </group>
          <group group_id="O9">
            <title>Chinese Cohort 3: TAK-831 600 mg</title>
            <description>TAK-831 600 mg, tablet, orally, once on Day 1 and once daily from Day 4 to Day 17 in healthy Chinese participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting at Least One TEAE Related to Vital Sign</title>
          <population>The safety analysis set was defined as all participants who received at least one dose of study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="2"/>
                <count group_id="O9" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reporting at Least One TEAE Related to Body Weight</title>
        <time_frame>Cohort 1: Baseline up to Day 23; Cohorts 2-5: Baseline up to Day 31</time_frame>
        <population>The safety analysis set was defined as all participants who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Japanese Cohort 1: Placebo</title>
            <description>TAK-831 matching placebo, tablets, orally, once on Day 1 of Part 1 and Day 1 (Day 9) of Part 2 in healthy Japanese participants.</description>
          </group>
          <group group_id="O2">
            <title>Japanese Cohort 1: TAK-831 100 mg</title>
            <description>TAK-831 100 mg, tablet, orally, once on Day 1 of Part 1 in healthy Japanese participants.</description>
          </group>
          <group group_id="O3">
            <title>Japanese Cohort 1: TAK-831 300 mg</title>
            <description>TAK-831 300 mg, tablet, orally, once on Day 1 (Day 9) of Part 2 in healthy Japanese participants.</description>
          </group>
          <group group_id="O4">
            <title>Japanese Cohort 2, 4 and 5: Pooled Placebo</title>
            <description>TAK-831 matching placebo, tablet, orally, once on Day 1 and once daily from Day 4 to Day 17 in healthy Japanese participants.</description>
          </group>
          <group group_id="O5">
            <title>Japanese Cohort 2: TAK-831 300 mg</title>
            <description>TAK-831 300 mg, tablet, orally, once on Day 1 and once daily from Day 4 to Day 17 in healthy Japanese participants.</description>
          </group>
          <group group_id="O6">
            <title>Japanese Cohort 4: TAK-831 600 mg</title>
            <description>TAK-831 600 mg, tablet, orally, once on Day 1 and once daily from Day 4 to Day 17 in healthy Japanese participants.</description>
          </group>
          <group group_id="O7">
            <title>Japanese Cohort 5: TAK-831 50 mg</title>
            <description>TAK-831 50 mg, tablet, orally, once on Day 1 and once daily from Day 4 to Day 17 in healthy Japanese participants.</description>
          </group>
          <group group_id="O8">
            <title>Chinese Cohort 3: Placebo</title>
            <description>TAK-831 matching placebo, tablet, orally, once on Day 1 and once daily from Day 4 to Day 17 in healthy Chinese participants.</description>
          </group>
          <group group_id="O9">
            <title>Chinese Cohort 3: TAK-831 600 mg</title>
            <description>TAK-831 600 mg, tablet, orally, once on Day 1 and once daily from Day 4 to Day 17 in healthy Chinese participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting at Least One TEAE Related to Body Weight</title>
          <population>The safety analysis set was defined as all participants who received at least one dose of study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="2"/>
                <count group_id="O9" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reporting at Least One TEAE Related to 12-lead Electrocardiogram (ECG) Parameters</title>
        <time_frame>Cohort 1: Baseline up to Day 23; Cohorts 2-5: Baseline up to Day 31</time_frame>
        <population>The safety analysis set was defined as all participants who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Japanese Cohort 1: Placebo</title>
            <description>TAK-831 matching placebo, tablets, orally, once on Day 1 of Part 1 and Day 1 (Day 9) of Part 2 in healthy Japanese participants.</description>
          </group>
          <group group_id="O2">
            <title>Japanese Cohort 1: TAK-831 100 mg</title>
            <description>TAK-831 100 mg, tablet, orally, once on Day 1 of Part 1 in healthy Japanese participants.</description>
          </group>
          <group group_id="O3">
            <title>Japanese Cohort 1: TAK-831 300 mg</title>
            <description>TAK-831 300 mg, tablet, orally, once on Day 1 (Day 9) of Part 2 in healthy Japanese participants.</description>
          </group>
          <group group_id="O4">
            <title>Japanese Cohort 2, 4 and 5: Pooled Placebo</title>
            <description>TAK-831 matching placebo, tablet, orally, once on Day 1 and once daily from Day 4 to Day 17 in healthy Japanese participants.</description>
          </group>
          <group group_id="O5">
            <title>Japanese Cohort 2: TAK-831 300 mg</title>
            <description>TAK-831 300 mg, tablet, orally, once on Day 1 and once daily from Day 4 to Day 17 in healthy Japanese participants.</description>
          </group>
          <group group_id="O6">
            <title>Japanese Cohort 4: TAK-831 600 mg</title>
            <description>TAK-831 600 mg, tablet, orally, once on Day 1 and once daily from Day 4 to Day 17 in healthy Japanese participants.</description>
          </group>
          <group group_id="O7">
            <title>Japanese Cohort 5: TAK-831 50 mg</title>
            <description>TAK-831 50 mg, tablet, orally, once on Day 1 and once daily from Day 4 to Day 17 in healthy Japanese participants.</description>
          </group>
          <group group_id="O8">
            <title>Chinese Cohort 3: Placebo</title>
            <description>TAK-831 matching placebo, tablet, orally, once on Day 1 and once daily from Day 4 to Day 17 in healthy Chinese participants.</description>
          </group>
          <group group_id="O9">
            <title>Chinese Cohort 3: TAK-831 600 mg</title>
            <description>TAK-831 600 mg, tablet, orally, once on Day 1 and once daily from Day 4 to Day 17 in healthy Chinese participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting at Least One TEAE Related to 12-lead Electrocardiogram (ECG) Parameters</title>
          <population>The safety analysis set was defined as all participants who received at least one dose of study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="2"/>
                <count group_id="O9" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax: Maximum Observed Plasma Concentration for TAK-831</title>
        <time_frame>Cohort 1: Day 1 pre-dose and at 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48 and 72 hours post-dose; Cohorts 2 to 5: Day 1 pre-dose and at 0.25, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48 and 72 hours post-dose</time_frame>
        <population>The pharmacokinetic (PK) analysis set included participants who received at least one dose of study drug, and who were appropriately evaluable for at least 1 PK parameter.</population>
        <group_list>
          <group group_id="O1">
            <title>Japanese Cohort 1: TAK-831 100 mg</title>
            <description>TAK-831 100 mg, tablet, orally, once on Day 1 of Part 1 in healthy Japanese participants.</description>
          </group>
          <group group_id="O2">
            <title>Japanese Cohort 1: TAK-831 300 mg</title>
            <description>TAK-831 300 mg, tablet, orally, once on Day 1 (Day 9) of Part 2 in healthy Japanese participants.</description>
          </group>
          <group group_id="O3">
            <title>Japanese Cohort 2: TAK-831 300 mg</title>
            <description>TAK-831 300 mg, tablet, orally, once on Day 1 and once daily from Day 4 to Day 17 in healthy Japanese participants.</description>
          </group>
          <group group_id="O4">
            <title>Japanese Cohort 4: TAK-831 600 mg</title>
            <description>TAK-831 600 mg, tablet, orally, once on Day 1 and once daily from Day 4 to Day 17 in healthy Japanese participants.</description>
          </group>
          <group group_id="O5">
            <title>Japanese Cohort 5: TAK-831 50 mg</title>
            <description>TAK-831 50 mg, tablet, orally, once on Day 1 and once daily from Day 4 to Day 17 in healthy Japanese participants.</description>
          </group>
          <group group_id="O6">
            <title>Chinese Cohort 3: TAK-831 600 mg</title>
            <description>TAK-831 600 mg, tablet, orally, once on Day 1 and once daily from Day 4 to Day 17 in healthy Chinese participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax: Maximum Observed Plasma Concentration for TAK-831</title>
          <population>The pharmacokinetic (PK) analysis set included participants who received at least one dose of study drug, and who were appropriately evaluable for at least 1 PK parameter.</population>
          <units>nanogram per milliliter (ng/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="985.5" spread="20.8"/>
                    <measurement group_id="O2" value="1823" spread="53.7"/>
                    <measurement group_id="O3" value="981.7" spread="29.1"/>
                    <measurement group_id="O4" value="1602" spread="42.1"/>
                    <measurement group_id="O5" value="339.9" spread="33.3"/>
                    <measurement group_id="O6" value="1807" spread="28.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cohorts 2 to 5, Cmax, ss: Maximum Observed Steady-state Plasma Concentration During a Dosing Interval for TAK-831</title>
        <time_frame>Day 17 pre-dose and at 0.25, 0.5, 1, 1.5, 2, 4, 8, 12 and 24 hours post-dose</time_frame>
        <population>The PK analysis set included participants who received at least one dose of study drug, and who were appropriately evaluable for at least 1 PK parameter.</population>
        <group_list>
          <group group_id="O1">
            <title>Japanese Cohort 2: TAK-831 300 mg</title>
            <description>TAK-831 300 mg, tablet, orally, once on Day 1 and once daily from Day 4 to Day 17 in healthy Japanese participants.</description>
          </group>
          <group group_id="O2">
            <title>Japanese Cohort 4: TAK-831 600 mg</title>
            <description>TAK-831 600 mg, tablet, orally, once on Day 1 and once daily from Day 4 to Day 17 in healthy Japanese participants.</description>
          </group>
          <group group_id="O3">
            <title>Japanese Cohort 5: TAK-831 50 mg</title>
            <description>TAK-831 50 mg, tablet, orally, once on Day 1 and once daily from Day 4 to Day 17 in healthy Japanese participants.</description>
          </group>
          <group group_id="O4">
            <title>Chinese Cohort 3: TAK-831 600 mg</title>
            <description>TAK-831 600 mg, tablet, orally, once on Day 1 and once daily from Day 4 to Day 17 in healthy Chinese participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Cohorts 2 to 5, Cmax, ss: Maximum Observed Steady-state Plasma Concentration During a Dosing Interval for TAK-831</title>
          <population>The PK analysis set included participants who received at least one dose of study drug, and who were appropriately evaluable for at least 1 PK parameter.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="831.8" spread="29.1"/>
                    <measurement group_id="O2" value="1903" spread="33.6"/>
                    <measurement group_id="O3" value="417.0" spread="23.8"/>
                    <measurement group_id="O4" value="1581" spread="42.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-831</title>
        <time_frame>Cohort 1: Day 1 pre-dose, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48, 72 hours post-dose; Cohorts 2 to 5: Day 1 pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48, 72 hours post-dose; Day 17 pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 8, 12, 24 hours post-dose</time_frame>
        <population>The PK analysis set included participants who received at least one dose of study drug, and who were appropriately evaluable for at least 1 PK parameter.</population>
        <group_list>
          <group group_id="O1">
            <title>Japanese Cohort 1: TAK-831 100 mg</title>
            <description>TAK-831 100 mg, tablet, orally, once on Day 1 of Part 1 in healthy Japanese participants.</description>
          </group>
          <group group_id="O2">
            <title>Japanese Cohort 1: TAK-831 300 mg</title>
            <description>TAK-831 300 mg, tablet, orally, once on Day 1 (Day 9) of Part 2 in healthy Japanese participants.</description>
          </group>
          <group group_id="O3">
            <title>Japanese Cohort 2: TAK-831 300 mg</title>
            <description>TAK-831 300 mg, tablet, orally, once on Day 1 and once daily from Day 4 to Day 17 in healthy Japanese participants.</description>
          </group>
          <group group_id="O4">
            <title>Japanese Cohort 4: TAK-831 600 mg</title>
            <description>TAK-831 600 mg, tablet, orally, once on Day 1 and once daily from Day 4 to Day 17 in healthy Japanese participants.</description>
          </group>
          <group group_id="O5">
            <title>Japanese Cohort 5: TAK-831 50 mg</title>
            <description>TAK-831 50 mg, tablet, orally, once on Day 1 and once daily from Day 4 to Day 17 in healthy Japanese participants.</description>
          </group>
          <group group_id="O6">
            <title>Chinese Cohort 3: TAK-831 600 mg</title>
            <description>TAK-831 600 mg, tablet, orally, once on Day 1 and once daily from Day 4 to Day 17 in healthy Chinese participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-831</title>
          <population>The PK analysis set included participants who received at least one dose of study drug, and who were appropriately evaluable for at least 1 PK parameter.</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5000" lower_limit="0.500" upper_limit="0.500"/>
                    <measurement group_id="O2" value="0.5000" lower_limit="0.500" upper_limit="1.00"/>
                    <measurement group_id="O3" value="2.000" lower_limit="1.50" upper_limit="4.00"/>
                    <measurement group_id="O4" value="1.750" lower_limit="1.50" upper_limit="4.00"/>
                    <measurement group_id="O5" value="0.5000" lower_limit="0.500" upper_limit="1.50"/>
                    <measurement group_id="O6" value="1.500" lower_limit="1.50" upper_limit="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Tmax for Cohort 1 was not planned to analyzed on Day 17.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Tmax for Cohort 1 was not planned to analyzed on Day 17.</measurement>
                    <measurement group_id="O3" value="1.750" lower_limit="1.00" upper_limit="4.000"/>
                    <measurement group_id="O4" value="2.000" lower_limit="1.00" upper_limit="4.00"/>
                    <measurement group_id="O5" value="0.5000" lower_limit="0.500" upper_limit="2.00"/>
                    <measurement group_id="O6" value="2.000" lower_limit="1.50" upper_limit="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUClast: Area Under the Plasma Concentration-time Curve (AUC) From Time 0 to Time of the Last Quantifiable Concentration for TAK-831</title>
        <time_frame>Cohort 1: Day 1 pre-dose and at 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48 and 72 hours post-dose; Cohorts 2 to 5: Day 1 pre-dose and at 0.25, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48 and 72 hours post-dose</time_frame>
        <population>The PK analysis set included participants who received at least one dose of study drug, and who were appropriately evaluable for at least 1 PK parameter.</population>
        <group_list>
          <group group_id="O1">
            <title>Japanese Cohort 1: TAK-831 100 mg</title>
            <description>TAK-831 100 mg, tablet, orally, once on Day 1 of Part 1 in healthy Japanese participants.</description>
          </group>
          <group group_id="O2">
            <title>Japanese Cohort 1: TAK-831 300 mg</title>
            <description>TAK-831 300 mg, tablet, orally, once on Day 1 (Day 9) of Part 2 in healthy Japanese participants.</description>
          </group>
          <group group_id="O3">
            <title>Japanese Cohort 2: TAK-831 300 mg</title>
            <description>TAK-831 300 mg, tablet, orally, once on Day 1 and once daily from Day 4 to Day 17 in healthy Japanese participants.</description>
          </group>
          <group group_id="O4">
            <title>Japanese Cohort 4: TAK-831 600 mg</title>
            <description>TAK-831 600 mg, tablet, orally, once on Day 1 and once daily from Day 4 to Day 17 in healthy Japanese participants.</description>
          </group>
          <group group_id="O5">
            <title>Japanese Cohort 5: TAK-831 50 mg</title>
            <description>TAK-831 50 mg, tablet, orally, once on Day 1 and once daily from Day 4 to Day 17 in healthy Japanese participants.</description>
          </group>
          <group group_id="O6">
            <title>Chinese Cohort 3: TAK-831 600 mg</title>
            <description>TAK-831 600 mg, tablet, orally, once on Day 1 and once daily from Day 4 to Day 17 in healthy Chinese participants.</description>
          </group>
        </group_list>
        <measure>
          <title>AUClast: Area Under the Plasma Concentration-time Curve (AUC) From Time 0 to Time of the Last Quantifiable Concentration for TAK-831</title>
          <population>The PK analysis set included participants who received at least one dose of study drug, and who were appropriately evaluable for at least 1 PK parameter.</population>
          <units>hour*nanogram per milliliter(h*ng/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1553" spread="11.8"/>
                    <measurement group_id="O2" value="3630" spread="11.9"/>
                    <measurement group_id="O3" value="3700" spread="32.2"/>
                    <measurement group_id="O4" value="6477" spread="26.2"/>
                    <measurement group_id="O5" value="847.4" spread="21.5"/>
                    <measurement group_id="O6" value="5504" spread="22.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUCâˆž: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-831</title>
        <time_frame>Cohort 1: Day 1 pre-dose and at 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48 and 72 hours post-dose; Cohorts 2 to 5: Day 1 pre-dose and at 0.25, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48 and 72 hours post-dose</time_frame>
        <population>The PK analysis set included participants who received at least one dose of study drug, and who were appropriately evaluable for at least 1 PK parameter.</population>
        <group_list>
          <group group_id="O1">
            <title>Japanese Cohort 1: TAK-831 100 mg</title>
            <description>TAK-831 100 mg, tablet, orally, once on Day 1 of Part 1 in healthy Japanese participants.</description>
          </group>
          <group group_id="O2">
            <title>Japanese Cohort 1: TAK-831 300 mg</title>
            <description>TAK-831 300 mg, tablet, orally, once on Day 1 (Day 9) of Part 2 in healthy Japanese participants.</description>
          </group>
          <group group_id="O3">
            <title>Japanese Cohort 2: TAK-831 300 mg</title>
            <description>TAK-831 300 mg, tablet, orally, once on Day 1 and once daily from Day 4 to Day 17 in healthy Japanese participants.</description>
          </group>
          <group group_id="O4">
            <title>Japanese Cohort 4: TAK-831 600 mg</title>
            <description>TAK-831 600 mg, tablet, orally, once on Day 1 and once daily from Day 4 to Day 17 in healthy Japanese participants.</description>
          </group>
          <group group_id="O5">
            <title>Japanese Cohort 5: TAK-831 50 mg</title>
            <description>TAK-831 50 mg, tablet, orally, once on Day 1 and once daily from Day 4 to Day 17 in healthy Japanese participants.</description>
          </group>
          <group group_id="O6">
            <title>Chinese Cohort 3: TAK-831 600 mg</title>
            <description>TAK-831 600 mg, tablet, orally, once on Day 1 and once daily from Day 4 to Day 17 in healthy Chinese participants.</description>
          </group>
        </group_list>
        <measure>
          <title>AUCâˆž: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-831</title>
          <population>The PK analysis set included participants who received at least one dose of study drug, and who were appropriately evaluable for at least 1 PK parameter.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1581" spread="11.7"/>
                    <measurement group_id="O2" value="3653" spread="12.2"/>
                    <measurement group_id="O3" value="3730" spread="31.9"/>
                    <measurement group_id="O4" value="6518" spread="26.2"/>
                    <measurement group_id="O5" value="923.6" spread="22.1"/>
                    <measurement group_id="O6" value="5530" spread="22.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cohorts 2 to 5, AUCtau: Area Under the Plasma Concentration-time Curve From Time 0 to [Time] Over the Dosing Interval for TAK-831</title>
        <time_frame>Day 1: pre-dose and at 0.25, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48 and 72 hours post-dose and Day 17: pre-dose and at 0.25, 0.5, 1, 1.5, 2, 4, 8, 12, and 24 hours post-dose</time_frame>
        <population>The PK analysis set included participants who received at least one dose of study drug, and who were appropriately evaluable for at least 1 PK parameter.</population>
        <group_list>
          <group group_id="O1">
            <title>Japanese Cohort 2: TAK-831 300 mg</title>
            <description>TAK-831 300 mg, tablet, orally, once on Day 1 and once daily from Day 4 to Day 17 in healthy Japanese participants.</description>
          </group>
          <group group_id="O2">
            <title>Japanese Cohort 4: TAK-831 600 mg</title>
            <description>TAK-831 600 mg, tablet, orally, once on Day 1 and once daily from Day 4 to Day 17 in healthy Japanese participants.</description>
          </group>
          <group group_id="O3">
            <title>Japanese Cohort 5: TAK-831 50 mg</title>
            <description>TAK-831 50 mg, tablet, orally, once on Day 1 and once daily from Day 4 to Day 17 in healthy Japanese participants.</description>
          </group>
          <group group_id="O4">
            <title>Chinese Cohort 3: TAK-831 600 mg</title>
            <description>TAK-831 600 mg, tablet, orally, once on Day 1 and once daily from Day 4 to Day 17 in healthy Chinese participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Cohorts 2 to 5, AUCtau: Area Under the Plasma Concentration-time Curve From Time 0 to [Time] Over the Dosing Interval for TAK-831</title>
          <population>The PK analysis set included participants who received at least one dose of study drug, and who were appropriately evaluable for at least 1 PK parameter.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3576" spread="30.6"/>
                    <measurement group_id="O2" value="6211" spread="26.8"/>
                    <measurement group_id="O3" value="794.5" spread="22.2"/>
                    <measurement group_id="O4" value="5340" spread="22.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2738" spread="31.1"/>
                    <measurement group_id="O2" value="8237" spread="28.4"/>
                    <measurement group_id="O3" value="983.0" spread="22.3"/>
                    <measurement group_id="O4" value="5839" spread="21.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 23 in Cohort 1 and up to Day 31 in Cohorts 2 to 5</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Japanese Cohort 1: Placebo</title>
          <description>TAK-831 matching placebo, tablets, orally, once on Day 1 of Part 1 and Day 1 (Day 9) of Part 2 in healthy Japanese participants.</description>
        </group>
        <group group_id="E2">
          <title>Japanese Cohort 1: TAK-831 100 mg</title>
          <description>TAK-831 100 mg, tablet, orally, once on Day 1 of Part 1 in healthy Japanese participants.</description>
        </group>
        <group group_id="E3">
          <title>Japanese Cohort 1: TAK-831 300 mg</title>
          <description>TAK-831 300 mg, tablet, orally, once on Day 1 (Day 9) of Part 2 in healthy Japanese participants.</description>
        </group>
        <group group_id="E4">
          <title>Japanese Cohort 2, 4 and 5: Pooled Placebo</title>
          <description>TAK-831 matching placebo, tablet, orally, once on Day 1 and once daily from Day 4 to Day 17 in healthy Japanese participants.</description>
        </group>
        <group group_id="E5">
          <title>Japanese Cohort 2: TAK-831 300 mg</title>
          <description>TAK-831 300 mg, tablet, orally, once on Day 1 and once daily from Day 4 to Day 17 in healthy Japanese participants.</description>
        </group>
        <group group_id="E6">
          <title>Japanese Cohort 4: TAK-831 600 mg</title>
          <description>TAK-831 600 mg, tablet, orally, once on Day 1 and once daily from Day 4 to Day 17 in healthy Japanese participants.</description>
        </group>
        <group group_id="E7">
          <title>Japanese Cohort 5: TAK-831 50 mg</title>
          <description>TAK-831 50 mg, tablet, orally, once on Day 1 and once daily from Day 4 to Day 17 in healthy Japanese participants.</description>
        </group>
        <group group_id="E8">
          <title>Chinese Cohort 3: Placebo</title>
          <description>TAK-831 matching placebo, tablet, orally, once on Day 1 and once daily from Day 4 to Day 17 in healthy Chinese participants.</description>
        </group>
        <group group_id="E9">
          <title>Chinese Cohort 3: TAK-831 600 mg</title>
          <description>TAK-831 600 mg, tablet, orally, once on Day 1 and once daily from Day 4 to Day 17 in healthy Chinese participants.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (21.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Post lumbar puncture syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Procedural headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vascular procedure complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Protein urine present</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Blood pressure systolic increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Red blood cells urine positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>White blood cells urine positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Blood urine present</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Papule</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takedaâ€™s sole discretion.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Takeda</organization>
      <phone>+1-877-825-3327</phone>
      <email>trialdisclosures@takeda.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

